Last reviewed · How we verify
Ifosfamide or dacarbazine
Ifosfamide and dacarbazine are alkylating agents that cross-link DNA to prevent cancer cell replication, while dacarbazine also acts as a prodrug requiring metabolic activation.
Ifosfamide and dacarbazine are alkylating agents that cross-link DNA to prevent cancer cell replication, while dacarbazine also acts as a prodrug requiring metabolic activation. Used for Soft tissue sarcoma (ifosfamide component), Melanoma (dacarbazine component), Lymphoma (both agents).
At a glance
| Generic name | Ifosfamide or dacarbazine |
|---|---|
| Sponsor | Institut Bergonié |
| Drug class | Alkylating agent |
| Target | DNA (non-specific alkylation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ifosfamide is a nitrogen mustard alkylating agent that forms covalent bonds with DNA, causing interstrand and intrastrand cross-links that block DNA replication and transcription. Dacarbazine is a triazene compound that requires hepatic metabolism to generate an active methylating species, which similarly alkylates DNA. Both agents are non-cell-cycle-specific and induce apoptosis in rapidly dividing cancer cells.
Approved indications
- Soft tissue sarcoma (ifosfamide component)
- Melanoma (dacarbazine component)
- Lymphoma (both agents)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Hemorrhagic cystitis (ifosfamide)
- Neurotoxicity/encephalopathy (ifosfamide)
- Alopecia
- Hepatotoxicity
- Renal dysfunction
Key clinical trials
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (PHASE3)
- Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors (PHASE2)
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (NA)
- Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma (PHASE3)
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma (PHASE2)
- Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) (PHASE2)
- Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma (PHASE2)
- Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |